Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Squamous Cell Carcinoma: early-phase trial registry
15 of 23 indexed Esophageal Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 15 currently recruiting · #724 of 28,707 conditions by registered trial count
Esophageal Squamous Cell Carcinoma: 23 US clinical trials tracked, 15 recruiting.
Esophageal Squamous Cell Carcinoma is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Seagen, a wholly owned subsidiary of Pfizer, running 2 of these trials.
Enrollment posture brief
Registry condition esophageal-squamous-cell-carcinoma
OPEN 15 | RECR 65% | LATE 4 | EARLY 16 | RANK #724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Emotion Regulation (65% recruiting · 26 trials)
Esophageal Squamous Cell Carcinoma lists 15 open slots (65% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esophageal Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esophageal Squamous Cell Carcinoma is recruiting above its size-band peers.
15 of 23 indexed trials (65.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Esophageal Squamous Cell Carcinoma trials is spread across many organizations.
Seagen, a wholly owned subsidiary of Pfizer accounts for 2 of 23 trials (8.7%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Esophageal Squamous Cell Carcinoma enrolment sits around 205 participants.
Median target enrolment is 205 among the 23 trials that report a genuine target (sentinel values excluded). 6 of those (26.1%) plan for fewer than 100 participants.
-
Esophageal Squamous Cell Carcinoma research is mostly interventional.
22 interventional and 1 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Daiichi Sankyo
NCT06644781
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Merck Sharp & Dohme
NCT06780111
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Merck Sharp & Dohme
NCT05319730
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics
NCT06747585
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United
NCT07217171
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium
NCT07284186
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development
NCT05563766
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics
NCT05144698
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Hoffmann-La Roche
NCT04543617
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
AstraZeneca
NCT04550260
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
NCT06084481
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
NCT04868877
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT04929392
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co.
NCT03748134
Esophageal Cytology With FISH in Detecting Esophageal Cancer
OHSU Knight Cancer Institute
NCT02100189
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
OHSU Knight Cancer Institute
NCT02890979
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 2 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Esophageal Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esophageal Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esophageal Squamous Cell Carcinoma page
23 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Esophageal Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seagen, a wholly owned subsidiary of Pfizer sponsors the most Esophageal Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See Seagen, a wholly owned subsidiary of Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Squamous Cell Carcinoma condition card totals 23 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.